Intact Drugs And Pharmaceuticlas.Ltd. Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 17-12-2024
- Paid Up Capital ₹ 1.91 M
as on 17-12-2024
- Company Age 32 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.38 Cr
as on 17-12-2024
- Revenue 42.88%
(FY 2022)
- Profit 153.59%
(FY 2022)
- Ebitda 753.46%
(FY 2022)
- Net Worth 9.85%
(FY 2022)
- Total Assets -10.27%
(FY 2022)
About Intact Drugs And Pharmaceuticlas.Ltd.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.91 M.
The company currently has active open charges totaling ₹1.38 Cr.
Naresh Goyal, Mukesh Kumar, and Kapil Goyal serve as directors at the Company.
- CIN/LLPIN
U24230DL1992PTC217567
- Company No.
217567
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Mar 1992
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Intact Drugs And Pharmaceuticlas.Ltd.?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Goyal  | Additional Director | 03-Jun-2024 | Current |
| Mukesh Kumar | Director | 21-Mar-2023 | Current |
| Kapil Goyal | Director | 23-Jun-2021 | Current |
Financial Performance of Intact Drugs And Pharmaceuticlas.Ltd..
Intact Drugs And Pharmaceuticlas Pvt.Ltd., for the financial year ended 2022, experienced significant growth in revenue, with a 42.88% increase. The company also saw a substantial improvement in profitability, with a 153.59% increase in profit. The company's net worth moved up by a moderate rise of 9.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intact Drugs And Pharmaceuticlas.Ltd.?
Unlock access to Intact Drugs And Pharmaceuticlas.Ltd.'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 09 Jan 2024 | ₹2.51 M | Open |
Axis Bank Limited Creation Date: 28 Nov 2023 | ₹0.57 M | Open |
Axis Bank Limited Creation Date: 12 Jan 2023 | ₹1.07 Cr | Open |
How Many Employees Work at Intact Drugs And Pharmaceuticlas.Ltd.?
Unlock and access historical data on people associated with Intact Drugs And Pharmaceuticlas.Ltd., such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intact Drugs And Pharmaceuticlas.Ltd., offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intact Drugs And Pharmaceuticlas.Ltd.'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
